ストックスクリーナーアプリを入手
3.12
2.50%
-0.08
前日終値:
$3.20
開ける：
$3.15
24時間の取引高:
282.79K
Relative Volume:
0.43
時価総額：
$736.26M
収益：
$596.48M
当期純損益:
$123.72M
株価収益率:
5.6893
EPS:
0.5484
ネットキャッシュフロー:
$106.59M
1週間 パフォーマンス:
+9.09%
1か月 パフォーマンス:
+1.63%
6か月 パフォーマンス:
+10.64%
1年 パフォーマンス:
+21.40%
1日の値動き範囲:
$3.07
$3.16
1週間の範囲:
$2.91
$3.29
52週間の値動き範囲:
$2.215
$5.28
Curevac N V Stock (CVAC) Company Profile
CVAC を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CVAC
Curevac N V
|
3.12 | 736.26M | 596.48M | 123.72M | 106.59M | 0.5484 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Curevac N V Stock (CVAC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-04-25 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2023-06-08 | 開始されました | SVB Securities | Outperform |
| 2023-01-19 | アップグレード | UBS | Neutral → Buy |
| 2023-01-09 | アップグレード | Jefferies | Hold → Buy |
| 2022-01-21 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-01-18 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-10-22 | 開始されました | Deutsche Bank | Hold |
| 2021-06-17 | ダウングレード | BofA Securities | Buy → Neutral |
| 2021-04-26 | 再開されました | Credit Suisse | Underperform |
| 2021-04-26 | 開始されました | Guggenheim | Neutral |
| 2020-12-10 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2020-09-08 | 開始されました | BofA Securities | Buy |
| 2020-09-08 | 開始されました | Credit Suisse | Neutral |
| 2020-09-08 | 開始されました | Jefferies | Hold |
すべてを表示
Curevac N V (CVAC) 最新ニュース
CureVac Among 3 Promising Penny Stocks To Watch - Yahoo Finance
CureVac (NASDAQ:CVAC) Trading Up 7.5% – Should You Buy? - Defense World
CureVac N.V. (NASDAQ:CVAC) Q4 2024 Earnings Call Transcript - Insider Monkey
CureVac N.V. Earnings Call: Financial Strength Amid Challenges - TipRanks
CureVac Stock Declines On Weaker-Than-Expected Q4 Revenue: Retail’s On Wait-And-Watch Mode - MSN
CureVac NV earnings beat by €0.06, revenue topped estimates - Investing.com South Africa
CureVac: 2025 will be less costly - marketscreener.com
CureVac N.V. Reports Earnings Results for the Full Year Ended December 31, 2024 - marketscreener.com
CureVac Announces Financial Results for the Fourth Quarter and F - GuruFocus
CureVac NV (CVAC) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Financial Resilience - Yahoo Finance
CureVac NV (CVAC) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Financial Resilience By GuruFocus - Investing.com Canada
CureVac NV (CVAC) Q4 2024 Earnings Call Highlights: Strategic Pa - GuruFocus
CureVac Reports Strong 2024 Financial Results and Strategic Progress - TipRanks
CureVac Reports 2024 Financial Results and Strategic Advances - TipRanks
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update - ACCESS Newswire
CureVac Q4 2024 Earnings Call Transcript - MarketBeat
Insights Ahead: CureVac's Quarterly Earnings - Benzinga
CureVac to initiate Phase 1 trial for its lung cancer therapy - MSN
FDA clears CureVac’s IND application for Phase I lung cancer trial - MSN
FDA clears Curevac’s IND for CVHNLC - BioWorld MedTech
EQS-News: CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025 - sharewise.com
CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025 - ACCESS Newswire
CureVac Financial Results: Key mRNA Biotech Player to Reveal 2024 Performance - Stock Titan
CureVac’s lung cancer therapy clears FDA hurdle - Investing.com Australia
CureVac’s lung cancer therapy clears FDA hurdle By Investing.com - Investing.com South Africa
CureVac's Early-stage Trial of Lung Cancer Drug Gets US FDA Clearance - MarketScreener
CureVac to initiate Phase 1 trial for its lung cancer therapy (CVAC:NASDAQ) - Seeking Alpha
CureVac Receives FDA Clearance to Initiate Phase 1 Trial of Lung Cancer Therapy - MarketScreener
EQS-News: CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer - sharewise.com
CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer - ACCESS Newswire
CureVac N.V.'s (NASDAQ:CVAC) Profit Outlook - simplywall.st
CureVac Announces Closing of $250 million Follow-on Public Offering of Common Shares - ACCESS Newswire
Is CureVac (CVAC) the Best German Stock to Buy According to Hedge Funds? - Yahoo Finance
CureVac and Novartis Sign Initial Agreement on Manufacturing of COVID-19 Vaccine Candidate, CVnCoV - ACCESS Newswire
CureVac (NASDAQ:CVAC) Stock Price Down 7.2%What's Next? - MarketBeat
CureVac: Patent Win Notable, But Won't Answer More Fundamental Questions (NASDAQ:CVAC) - Seeking Alpha
CureVac (CVAC) Stock Surges After Favorable Patent Ruling - Stocks Telegraph
European Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock Jumps - Benzinga
Lululemon, General Motors and Apple fall premarket; CureVac gains By Investing.com - Investing.com Canada
Lululemon, General Motors and Apple fall premarket; CureVac gains - Investing.com India
CureVac, gold miners, Rocket Lab - TradingView
CureVac Patent Validated in BioNTech Dispute, Infringement Hearing Set for July - Marketscreener.com
PRTG Soars On Mesothelioma Data, NVNO Awaits FDA Decision, CureVac Jumps On Patent News - RTTNews
CureVac’s amended patent upheld by European Patent Office By Investing.com - Investing.com South Africa
European Patent Office declares CureVac mRNA patent valid - Marketscreener.com
CureVac up 13% as court upholds validity of patent in BioNTech spat - Seeking Alpha
Curevac N V (CVAC) 財務データ
収益
当期純利益
現金流量
EPS
2.51%
大文字化:
|
ボリューム (24 時間):